Which formulation is indicated for chronic lung disease?

Which formulation is indicated for chronic lung disease?

• A. Low carbohydrate formula
• B. Hydrolyzed protein formula
• C. MCT oil predominant formula
• D. None of these

Answer: (D)

Chronic lung disease is managed with nutrition by ensuring adequate calories and protein, while avoiding overfeeding that can raise CO2 production. There isn’t a single enteral formula that is universally indicated just for chronic lung disease. The options described correspond to uses in other situations, not a specific CLD indication. A low carbohydrate formula could theoretically reduce CO2 production, but it isn’t a universally recommended approach for CLD and carries risks like ketosis or inadequate overall nutrition. A hydrolyzed protein formula is chosen when there is poor digestion/absorption or protein allergies, not because of lung disease. An MCT oil–predominant formula is typically used for fat malabsorption or specific GI/absorption issues, not as a standard for chronic lung disease. Therefore, none of these formulations is specifically indicated for CLD. In practice, focus on meeting energy and protein goals, monitor tolerance, and tailor the plan to the patient’s GI function and overall metabolic needs rather than selecting a CLD-specific formula.

Chronic lung disease is managed with nutrition by ensuring adequate calories and protein, while avoiding overfeeding that can raise CO2 production. There isn’t a single enteral formula that is universally indicated just for chronic lung disease. The options described correspond to uses in other situations, not a specific CLD indication.

A low carbohydrate formula could theoretically reduce CO2 production, but it isn’t a universally recommended approach for CLD and carries risks like ketosis or inadequate overall nutrition. A hydrolyzed protein formula is chosen when there is poor digestion/absorption or protein allergies, not because of lung disease. An MCT oil–predominant formula is typically used for fat malabsorption or specific GI/absorption issues, not as a standard for chronic lung disease. Therefore, none of these formulations is specifically indicated for CLD.

In practice, focus on meeting energy and protein goals, monitor tolerance, and tailor the plan to the patient’s GI function and overall metabolic needs rather than selecting a CLD-specific formula.